References
- 1. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science. 1960; 132: 1497.
- 2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogeneus leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243: 290-293.
- 3. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph’ translocation. Nature. 1985; 315: 758-761.
- 4. Collins SJ, Kubonishi I, Miyoshi I, Groudine M. Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. Science. 1984; 225: 72-74.
- 5. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.
- 6. Goldman JM, Melo JV. Chronic Myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003; 349(15): 1451-64.
- 7. Hughes TP, Kaeda J, Branford S, Rudzi Z, Hochhaus A, Hensly ML, et al. Frequency of major molecular response to imatinib or intereferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Eng J Med. 2003; 349(15): 1423-32.
- 8. O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International Randomized study of Interferon versus STI571 (IRIS) 7- year follow-up: sustained survival, low rate of transformation and increase rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood. 2008; 112: Abstract 186.
- 9. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperly JF, et al. European Leukemia Net recommendations for management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872-884.
- 10. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(11): 1018-1029.
- 11. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(12): 1116-1128.
- 12. Soverini S, Hochhaus A, Nicolini FE, et al. BCRABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European Leukemia Net. Blood. 2011; 118(5): 1208-1215.
- 13. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003; 101(10): 3794-3800.
- 14. Deininger MWN, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007; 110(7): 1509-1519.
- 15. Lee SE, Choi SY, Bang JH, et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet. 2012; 205(11): 563-571.
- 16. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, et al. Five-year follow-up of patient receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23): 2408-17.
- 17. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained response in an intention-to treat analysis. J Clin Oncol. 2008; 26(20): 3358-63.
- 18. Hehlmann R, Lauseker M, Junk-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011; 29(12): 1634-42.
- 19. Cortes JE, Kantarjian HM, Goldberg SL, et al. Highdose imatinib in newly diagnosed chronic myeloid leukemia: high rates of rapid cytogenetic and molecular response. J Clin Oncol. 2009; 27(28): 4754-9.